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Materials and Methods: Patients and samples
Patients with advanced GC who received anti-PD-1 mAb (nivolumab) from October to December 2017 and underwent at least one image evaluation for clinical responses until 2 months after the initial drug administration at National Cancer Center Hospital East were enrolled in this study (Table S1 ). FFPE slides from pre-treatment biopsy specimens were used for genome analyses, and fresh paired tumor samples obtained from primary or metastatic tumor by endoscopic or needle biopsy at pre-and post-nivolumab (just before the initial drug administration and at first evaluation, respectively) were subjected to immunological assays. Patients with Eastern Clinical Oncology Group PS 2 or higher were excluded from this study. In addition, 22 patients with GC who underwent surgical resection at National Cancer Center Hospital East from September to December 2015 were also enrolled for TIL analyses ( Table S5) .
Definition of HPD
Tumor size was evaluated as the sum of the longest diameters of the target lesions following the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria (1) .
HPD was defined as previously reported; time-to-treatment failure <2 months, >50% increase in tumor burden compared with pre-treatment imaging, and >2-fold increase in progression speed (2) .
Immunohistochemistry
Anti-PD-L1 mAb (SP263, Ventana, Tucson, AZ) was used for IHC using an automatic staining instrument (BenchMark ULTRA, Ventana). PD-L1 positivity was defined as staining in 1% or more in tumor or stroma cells. Multiplexed fluorescent immunohistochemistry was performed by the TSA method using an Opal IHC kit (PerkinElmer, Waltham, MA) according to the manufacturer's instructions. Anti-human CD4 mAb [clone 4B12, DAKO, Glostrup, Denmark, working concentration (WC) 10 μg/ml], anti-human FoxP3 mAb (clone 236A/E7, Abcam, Cambridge, UK, WC 8 μg/ml) were used as primary antibodies. Multiplexed fluorescent labeled images of three randomly selected fields (669x500 micrometer) were captured with an automated imaging system (Vectra ver3.0, PerkinElmer). Cell counts were performed manually on each image.
Evaluation of mismatch repair (MMR) status
MMR status was examined with IHC with anti-mutLhomolog 1 (MLH1; ES05) mAb, anti-mutS homolog 2 (MSH2; FE11) mAb, anti-postmeiotic segregation increased 2 (PMS2; EP51) mAb, and anti-mutShomolog 6 (MSH6; EP49) mAb (Dako, Copenhagen, Denmark). Tumors were considered negative for MLH1, MSH2, PMS2, or MSH6 expression only if there was a complete absence of nuclear staining in the tumor cells, and normal epithelial cells and lymphocytes were used as an internal control. Tumors lacking MLH1, MSH2, PMS2, or MSH6 expression were defined as MMR deficient, whereas tumors that maintained expression of all markers were considered MMR proficient.
Evaluation of Epstein-Barr virus (EBV) infection
Chromogenic in situ hybridization (ISH) for EBV-encoded RNA was performed with fluorescein-labeled oligonucleotide probes (INFORM EBER probe) with enzymatic digestion (ISH protease 3, Ventana) and an iViewBlue detection kit (Ventana) with use of the BenchMark ULTRA staining system.
Genomic analysis
DNA and RNA were extracted from FFPE tumor samples and were subjected to the Oncomine™ Comprehensive Assay version 3 (Thermo Fisher Scientific) which allows to detect gene mutations, copy number variants and fusions across multiple genes ( Table   S3 ). The detected genomic variant data were classified according to genetic drivers of cancer including gain-and loss-of-function mutations or single nucleotide variants based on the Oncomine Knowledgebase.
PBMC and TIL analysis
PBMCs were isolated by density gradient centrifugation with Ficoll-Paque (GE Healthcare, Little Chalfont, UK). To collect TILs, tumor tissues were minced and treated with gentleMACS Dissociator (Miltenyi Biotec), as previously described (3) and the prepared cells (TILs) were subjected to flow cytometric analysis.
Animal procedures
C57BL/6J mice were purchased from CLEA, Japan (Tokyo, Japan). CD45.1 C57BL/6J mice were maintained in Osaka University animal facility. Mice on CD4
Cre (4) All mice were maintained in specific pathogen free facility in Osaka University.
All experiments were approved by the Institutional Review Board and performed according to guidelines for animal welfare set by Osaka University.
Flow cytometry for human samples
Cells, washed by PBS with 2% fetal calf serum, were stained with mAbs specific for CD3, Table S6 .
Flow cytometry for mouse samples
Single cell suspensions were prepared from tumors, spleen and lymph nodes. Cells were first incubated with anti-CD16/32 then stained with Live/Dead cell viability dye, and antibodies for surface markers as follows. B220, CD45. and/or anti-PD-1 mAb in the presence of anti-CD3 mAb and anti-CD28 mAb (Thermo Fisher Scientific). Forty-eight hours after incubation, cellular proliferation was evaluated using WST-1 assay (TaKaRa, Shiga, Japan).
Statistical analysis
The patient characteristics were compared between HPD and non-HPD using the Fisher exact test. Continuous variables were analyzed using t-test. The statistical analyses were two-tailed and were performed using Prism version 7 software (GraphPad Software, Inc., La Jolla, CA). A P-value of less than 0.05 was considered statistically significant. For mouse experiments, comparisons between two experimental groups were carried out using non-parametric Mann-Whitney U test. Two-way ANOVA and Sidak's multiple comparisons test were applied in grouped analyses for in vitro suppression assay and tumor growth kinetics. Data are presented as mean  SEM and analyzed using GraphPad Prism as above. P<0.05 was considered statistically significant.
Fig. S1. Genomic features of patients who experienced HPD during PD-1 blockade treatment.
DNA and RNA extracted from FFPE tumor samples (3 HPD patients and 18 non-HPD patients) were subjected to the Oncomine™ Comprehensive Assay version 3, that can detect gene mutations, copy number variants and fusions across multiple genes (Table   S3) . Gene alterations are shown in red (amplification) and black (mutation). One among three patients with HPD possessed an MDM2 gene amplification, whereas no patients without HPD had MDM2 gene family alterations. Other gene alterations found in patients with HPD (ERBB2 amplification, KRAS amplification, TP53 mutation, and PIK3CA mutation) were also detected in non-HPD patients. PD-1 + eTreg cells were sorted from PBMCs using FACS Aria fusion and PD-1 expression was confirmed before using suppression and cellular proliferation assays. TILs were collected from surgically resected GC samples (Table S5) CHEK2  NF2  FGFR1  ETV5  CSF1R  NOTCH1  FGFR2  FGFR1  CTNNB1  PIK3R1  FGFR3  FGFR2  DDR2  PTCH1  FGFR4  FGFR3  EGFR  PTEN  FLT3  NTRK1  ERBB2  RB1  IGF1R  NTRK3  ERB83  SMARCB1  KIT  PDGFRA  ERBB4  STK11  KRAS  PPARG  ESR1  TP53  MDM2  RAF1  EZH2  TSC1  MDM4  RET  FGFR1  TSC2  MET  ROS1  FGFR2  ARID1A  MYC  AKT2  FGFR3  ATR  MYCL  AR  FLT3  ATRX  MYCN  BRCA1  FOXL2  CDK12  PDGFRA  BRCA2  GATA2  CDKN1B  PIK3CA  CDKN2A  GNA11  CDKN2B  PPARG  ERB84  GNAQ  CHEK1  TERT  ESR1  GNAS  CREBBP  AKT2  FGR  HNF1A  FANCA  AKT3  FLT3  HRAS  FANCD2  ALK  JAK2  IDH1  FANCI  AXL  KRAS  IDH2  MLH1  BRAF  MDM4  JAK1  MRE11A  CCND2  MET  JAK2  MSH6  CCND3  MYB  JAK3  NBN  CDK2  MYBL1  KDR  NOTCH2  CDKN2A  NF1  KIT  NOTCH3  CDKN2B  NOTCH1  KNSTRN  PALB2  ESR1  NOTCH4  KRAS  PMS2  FGF19  NRG1  MAGOH  POLE  FGF3  NTRK2  MAP2K1  RAD50  NTRK1  NUTM1 6 
